Quinapril: A further update of its pharmacology and therapeutic use in cardiovascular disorders

Drugs

Volumn 62, Issue 2, 2002, Pages 339-385

  Culy, Christine R ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Congestive heart failure; Coronary artery disease; Hypertension; Pharmacodynamics; Pharmacokinetics; Quinapril; Therapeutic use

Indexed keywords

ACETYLCHOLINE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN I; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; N(G) METHYLARGININE; NITRENDIPINE; NITRIC OXIDE; QUINAPRIL; QUINAPRILAT; TETRACYCLINE; WARFARIN;

ABDOMINAL PAIN; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; MYALGIA; NAUSEA; RASH; REVIEW; THORAX PAIN; VERTIGO; VOMITING;

EID: 0036178006     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262020-00009     Document Type: Review

References (244)

1. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
2. Quinapril: A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders
3. Quinapril: A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders
4. Manipulation of the renin-angiotensin system
5. Angiotensin-converting enzyme inhibitors
6. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease
7. Actions of angiotensin on adrenergic nerve endings
8. Mechanism of protective effects of ACE inhibition on coronary artery disease
9. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure
10. The angiotensin I converting enzyme
11. Endothelium and control of vascular function. State of the Art lecture
12. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors
13. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
14. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
15. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue
16. Angiotensin converting enzyme binding sites in human heart and lung: Comparison with rat tissues
17. Measurement of angiotensin I converting enzyme inhibition in the heart
18. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure: Role of plasma versus tissue ACE
19. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure
20. A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril
21. Angiotensin II formation in human vasculature after chronic ACE inhibition: A prospective, randomized, placebo-controlled study
22. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors
23. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans
24. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
25. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats
26. Bradykinin contributes to the cardiac reparation by quinapril in rats with hypertensive left ventricular hypertrophy
27. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: Possible mechanisms
28. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: Role of bradykinin
29. Effects of the converting ensyme inhibitor quinapril on the circadian rhythm of blood pressure and heart rate in essential hypertension
30. Short report: Ambulatory blood pressure monitoring can play an integral role in patient selection, dosage adjustment and efficacy assessment in clinical trials of antihypertensive agents
31. A comparative study of the effects of lisinopril and quinapril administered once a day in essential hypertension
32. Duration of action of angiotensin converting enzyme inhibitors
33. A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension
34. Preliminary hemodynamic report of the efficacy and safety of quinapril in acute and chronic treatment of patients with congestive heart failure
35. The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure
36. The hemodynamic effects of ACE inhibitors in the treatment of congestive heart failure
37. Effect of quinapril on blood pressure and heart rate in congestive heart failure
38. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm
39. Treatment of mild-to-moderate congestive heart failure with the angiotensin converting enzyme inhibitor quinapril
40. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure
41. Dose-related effects of ACE inhibition in man: Quinapril in patients with moderate congestive heart failure
42. Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension
43. Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients
44. Angiotensin converting enzyme inhibition with quinapril and left ventricular mass in the hypertensive patient: A 4-month echocardiographic study
45. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors
46. Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy
47. Insulin-like growth factor-1 and cardiac mass in essential hypertension: Comparative effects of captopril, lisinopril and quinapril
48. Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation
49. Hemodynamic and morphologic changes after long-term angiotensin converting enzyme inhibition in patients with chronic valvular regurgitation
50. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors
51. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications
52. Effect of quinapril initiated during progressive remodeling in asymptomatic patients with healed myocardial infarction
53. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
54. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone
55. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor
56. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease
57. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
58. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
59. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions
60. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited
61. Nitric oxide activity in the human coronary circulation: Impact of risk factors for coronary atherosclerosis
62. A rationale for treatment of endothelial dysfunction in hypertension
63. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: A future therapeutic perspective
64. Effects of antihypertensive agents on endothelial dysfunction: Rationale for the brachial artery normalization of forearm function study
65. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
66. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
67. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function
68. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
69. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension
70. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins
71. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
72. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans
73. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study
74. Mechanism by which quinapril improves vascular function in coronary artery disease
75. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol
76. Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function
77. Metabolism and excretion of nitric oxide in humans: An experimental and clinical study
78. Negative feedback regulation of endothelial cell function by nitric oxide
79. Effects of single doses of quinapril and atenolol on autonomic nervous function and exercise capacity in healthy volunteers
80. Effects of the converting enzyme inhibitor quinapril on autonomic function in normotensive and essential hypertensive subjects
81. Converting enzyme inhibition attenuates the noradrenaline response to the Valsalva manoeuvre
82. Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction
83. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients
84. Effect of angiotensin-converting enzyme inhibitors on the power spectrum of heart rate variability in post-myocardial infarction patients
85. Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction
86. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction
87. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy
88. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy
89. Regression of left ventricular hypertrophy and improvement of renal hemodynamics in hypertensive patients treated with quinapril
90. Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension
91. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
92. Renal protection and antihypertensive drugs: Current status
93. Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure
94. Antihypertensive agents, serum lipoproteins and glucose metabolism
95. Overall tolerance and safety of quinapril in clinical trials
96. Effect of antihypertensive therapy with quinapril on blood lipids
97. Blood lipid changes in hypertensive, dyslipidemic patients under long term quinapril treatment
98. Quinapril and blood lipids
99. A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow-up with ABPM spa
100. Modification of cardiovascular risk factors during antihypertensive treatment: A multicentre trial with quinapril
101. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension
102. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects
103. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension
104. Quinapril treatment enhances vascular sensitivity to insulin
105. Insulin sensitivity, glucose effectiveness, and b-cell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril)
106. The clinical pharmacokinetics of quinapril
107. A pharmacokinetic study of quinapril in normal Japanese men Japanese
108. A clinical phase 1 study of quinapril Japanese
109. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors
110. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928
111. Comparative pharmacokinetics of captopril, enalapril, and quinapril
112. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril
113. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with renal insufficency
114. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment
115. Pharmacokinetics of quinapril in patients with renal dysfunction
116. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure
117. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis
118. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis
119. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with hepatic impairment
120. Pharmacokinetic alterations of quinapril during repeated treatment in elderly subjects
121. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure
122. Quinapril and its metabolite quinaprilat in human milk
123. A study to determine the relationship of the tetracycline-quinapril pharmacokinetic (PK) interaction with the timing of concurrent drug administration
124. Quinapril: A double-blind, placebo-controlled trial in essential hypertension
125. Quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension
126. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension
127. A parallel group double-blind study of once daily quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension
128. The treatment of mild to moderate hypertension with ACE inhibitors
129. A parallel group double-blind study of once-daily quinapril versus twice-daily captopril in the treatment of mild to moderate essential hypertension
130. Quinapril and lisinopril in elderly patients with mild-to-moderate hypertension: A randomised, double blind comparison
131. Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring
132. Quinapril versus atenolol in the treatment of mild to moderate essential hypertension
133. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker
134. Quinapril and nifedipine in mild to moderate hypertension. A randomised, open, multicentre, parallel group comparison
135. Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension
136. Comparison of antihypertensive efficacy and tolerance of quinapril and nitrendipine German
137. The treatment of moderate to severe hypertension with ACE inhibitors
138. Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension
139. The efficacy and safety of quinapril in the treatment of moderate to severe and severe hypertension: Comparison to captopril
140. Efficacy and safety of quinapril 40mg once daily as monotherapy for patients with poorly controlled hypertension: The EUREKA study
141. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: The ACCEPT study. Accupril Canadian Clinical Evaluation and Patient Teaching
142. ASCEND (Accupril Study of Clinical, Economic, and Dose Titration End Points): Demographics and special population results
143. ASCEND (Accupril Study of Clinical, Economic, and Dose Titration End Points): Design, rationale, general results
144. ASCEND (Accupril Study of Clinical, Economic, and Dose Titration End Points): Effect of up titration and compliance on response rate
145. Efficacy and safety of quinapril in the elderly hypertensive patient
146. The management of hypertension in older patients
147. The effectiveness of quinapril in hypertensive patients over 60 years old
148. Effect of race on hypertension and antihypertensive therapy
149. Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension
150. Efficacy and safety of quinapril in long-term treatment of essential hypertension Japanese
151. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: The Quinapril Titration Interval Management Evaluation (ATIME) study
152. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
153. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
154. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
155. Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension
156. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications
157. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
158. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data
159. Effect if ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials
160. Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker
161. Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension
162. Effects of lisinopril and nitrendipine on urinary albumin excretion and renal function in patients with mild to moderate essential hypertension
163. Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs
164. Long-term captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment
165. Microalbuminuria in essential hypertension: Reduction by different antihypertensive drugs
166. Albumin excretion rate and metabolic modifications in patients with essential hypertension: Effects of two angiotensin converting enzyme inhibitors
167. Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension
168. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure
169. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure
170. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double-blind, placebo-controlled study of quinapril
171. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
172. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
173. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
174. Effect of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
175. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
176. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
177. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators
178. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
179. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
180. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
181. Consensus recommendations for the management of chronic heart failure. On behalf of the Steering Committee and the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure
182. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure
183. Quinapril in patients with congestive heart failure: Controlled trial versus captopril
184. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure
185. Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure
186. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia
187. The Quinapril Ischemic Event Trial (QUIET): Evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function
188. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
189. New strategies to prevent restenosis
190. Quinapril with high affinity to tissue angiotensin-converting enzyme inhibitor reduces restenosis after percutaneous transcatheter coronary revascularization
191. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound
192. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial
193. The safety and tolerability of quinapril
194. Multicentric study of quinapril, an angiotensin converting enzyme inhibitor in the treatment of mild to moderate essentional hypertension
195. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
196. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
197. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommittee
198. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
199. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
200. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
201. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
202. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomized trials
203. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
204. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension
205. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
206. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
207. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
208. Ramipril and the development of diabetes
209. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy
210. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies
211. Prognostic significance of serial changes in left ventricular mass in essential hypertension
212. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
213. The treatment of heart failure
214. North of England evidence based development project: Guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure
215. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
216. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
217. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
218. Clinical trials update: Highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
219. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
220. The effect of digoxin on mortality and morbidity in patients with heart failure
221. Overview of the treatment of heart failure
222. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
223. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing
224. Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction
225. Advances in the treatment of congestive heart failure: New approaches for an old disease
226. Treatment of congestive heart failure: Guidelines for the primary care physician and the heart failure specialist
227. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other societies on coronary prevention
228. Preventing heart attack and death in patients with coronary disease
229. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
230. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
231. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
232. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: A review of clinical investigations
233. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study
234. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina
235. Short-term effects of captopril on exercise tolerance in patients with chronic stable angina pectoris and normal left ventricular function
236. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure
237. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)
238. ACC/AHA guidelines for coronary artery bypass graft surgery: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery)
239. The continuation of the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial
240. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA)